Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Pharmaceutics · 22.04.2023 · 15 (5) · 1318
DOI: 10.3390/pharmaceutics15051318 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 22.04.2023. Verfasst von Oluwabukunmi Olajubutu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Howard University, Washington, DC 20059, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HRSA Center of Excellence.
Abstract (Originalsprache)
Pancreatic cancer is fast becoming a global menace and it is projected to be the second leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which develop in the pancreas’ exocrine region, are the predominant type of pancreatic cancer, representing about 95% of total pancreatic tumors. The malignancy progresses asymptomatically, making early diagnosis difficult. It is characterized by excessive production of fibrotic stroma known as desmoplasia, which aids tumor growth and metastatic spread by remodeling the extracellular matrix and releasing tumor growth factors. For decades, immense efforts have been harnessed toward developing more effective drug delivery systems for pancreatic cancer treatment leveraging nanotechnology, immunotherapy, drug conjugates, and combinations of these approaches. However, despite the reported preclinical success of these approaches, no substantial progress has been made clinically and the prognosis for pancreatic cancer is worsening. This review provides insights into challenges associated with the delivery of therapeutics for pancreatic cancer treatment and discusses drug delivery strategies to minimize adverse effects associated with current chemotherapy options and to improve the efficiency of drug treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Howard University, Washington, DC 20059, USA.
ORCID-Profile: Omotola D Ogundipe
Förderung
- HRSA Center of Excellence
Zitieren
APA
Olajubutu, O., Ogundipe, O. D., Adebayo, A., & Adesina, S. K. (2023). Drug Delivery Strategies for the Treatment of Pancreatic Cancer. Pharmaceutics, 15(5), 1318. https://doi.org/10.3390/pharmaceutics15051318
Vancouver
Olajubutu O, Ogundipe OD, Adebayo A, Adesina SK. Drug Delivery Strategies for the Treatment of Pancreatic Cancer. Pharmaceutics. 2023;15(5):1318. doi:10.3390/pharmaceutics15051318
BibTeX
@article{Olajubutu2023,
author = {Olajubutu, Oluwabukunmi and Ogundipe, Omotola D and Adebayo, Amusa and Adesina, Simeon K},
title = {Drug Delivery Strategies for the Treatment of Pancreatic Cancer},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1318},
doi = {10.3390/pharmaceutics15051318}
}
EUVIMED